Alvotech (ALVO)

Market Cap	1.53B
Revenue (ttm)	562.48M
Net Income (ttm)	63.36M
Shares Out	313.02M
EPS (ttm)	0.22
PE Ratio	22.44
Forward PE	20.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	898,101
Open	4.860
Previous Close	4.830
Day's Range	4.830 - 5.070
52-Week Range	4.700 - 13.700
Beta	0.10
Analysts	Buy
Price Target	11.00 (+125.41%)
Earnings Date	Nov 12, 2025

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: NASDAQ
• Ticker Symbol: ALVO
• Website: https://www.alvotech.com

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for ALVO stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 125.41% from the latest price.

Price Target

$11.0

(125.41% upside)

Analyst Consensus: Buy